Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by stockman6767on Jun 14, 2014 10:38pm
249 Views
Post# 22661150

Affymax, Takeda End Anemia Drug Partnership

Affymax, Takeda End Anemia Drug Partnership

Affymax, Takeda End Anemia Drug Partnership

By Dow Jones Business News,


Affymax Inc. (AFFY) and Takeda Pharmaceutical Co. Ltd. (TKPYY) said they will end their anemia drug Omontys partnership in September and withdraw an application with the U.S. Food and Drug Administration.

Sell AAPL Today?

I'm Steve Reitmeister with Zacks Investment Research. We're releasing a free AAPL analysis that forecasts where it's heading in 1-3 months.

This prediction model is worth noting because it nearly triples the market's average yearly gain.

Important: A second free report based on that model reveals all of Zacks' MUST-SELL stocks. See if AAPL or any of your holdings are on this list.
Get both free reports right now »

The companies had recalled the drug, which was used in kidney dialysis patients, in February 2013 following reports of serious hypersensitivity reaction including anaphylaxis, a life-threatening allergic reaction.

A total of 98 "adverse events" tied to the drug were reported to the FDA, including 12 deaths, by Feb. 22, 2013, the day before the recall.

The cause of the deaths wasn't specified.

Takeda said at the time there were five deaths that the companies considered in deciding to recall the Omontys lots.

An internal investigation by Takeda found no quality or manufacturing issues but failed to identify the cause of the reactions, the companies said in a statement.

The Osaka, Japan-based Takeda said the termination won't affect its outlook for the fiscal year.

Affymax, of Cupertino, Calif., said its board of directors is reviewing its strategic options.

In March, Affymax said it would cut its workforce by 75% and was considering selling itself.



Read more: https://www.nasdaq.com/article/affymax-takeda-end-anemia-drug-partnership-20140613-00621#ixzz34fgCVaw9
Bullboard Posts